The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate. Bobardt, M., Kuo, J., Chatterji, U., Chanda, S., Little, S. J., Wiedemann, N., Vuagniaux, G., & Gallay, P. A. PloS One, 14(2):e0211746, 2019. doi abstract bibtex Antiretroviral therapy (ART) suppresses HIV replication, but does not cure the infection because replication-competent virus persists within latently infected CD4+ T cells throughout years of therapy. These reservoirs contain integrated HIV-1 genomes and can resupply active virus. Thus, the development of strategies to eliminate the reservoir of latently infected cells is a research priority of global significance. In this study, we tested efficacy of a new inhibitor of apoptosis protein antagonist (IAPa) called Debio 1143 at reversing HIV latency and investigated its mechanisms of action. Debio 1143 activates HIV transcription via NF-kB signaling by degrading the ubiquitin ligase baculoviral IAP repeat-containing 2 (BIRC2), a repressor of the non-canonical NF-kB pathway. Debio 1143-induced BIRC2 degradation results in the accumulation of NF-κB-inducing kinase (NIK) and proteolytic cleavage of p100 into p52, leading to nuclear translocation of p52 and RELB. Debio 1143 greatly enhances the binding of RELB to the HIV-1 LTR. These data indicate that Debio 1143 activates the non-canonical NF-kB signaling pathway by promoting the binding of RELB:p52 complexes to the HIV-1 LTR, resulting in the activation of the LTR-dependent HIV-1 transcription. Importantly, Debio 1143 reverses viral latency in HIV-1 latent T cell lines. Using knockdown (siRNA BIRC2), knockout (CRIPSR NIK) and proteasome machinery neutralization (MG132) approaches, we found that Debio 1143-mediated HIV latency reversal is BIRC2 degradation- and NIK stabilization-dependent. Debio 1143 also reverses HIV-1 latency in resting CD4+ T cells derived from ART-treated patients or HIV-1-infected humanized mice under ART. Interestingly, daily oral administration of Debio 1143 in cancer patients at well-tolerated doses elicited BIRC2 target engagement in PBMCs and induced a moderate increase in cytokines and chemokines mechanistically related to NF-kB signaling. In conclusion, we provide strong evidences that the IAPa Debio 1143, by initially activating the non-canonical NF-kB signaling and subsequently reactivating HIV-1 transcription, represents a new attractive viral latency reversal agent (LRA).
@article{bobardt_inhibitor_2019,
title = {The inhibitor apoptosis protein antagonist {Debio} 1143 {Is} an attractive {HIV}-1 latency reversal candidate},
volume = {14},
issn = {1932-6203},
doi = {10.1371/journal.pone.0211746},
abstract = {Antiretroviral therapy (ART) suppresses HIV replication, but does not cure the infection because replication-competent virus persists within latently infected CD4+ T cells throughout years of therapy. These reservoirs contain integrated HIV-1 genomes and can resupply active virus. Thus, the development of strategies to eliminate the reservoir of latently infected cells is a research priority of global significance. In this study, we tested efficacy of a new inhibitor of apoptosis protein antagonist (IAPa) called Debio 1143 at reversing HIV latency and investigated its mechanisms of action. Debio 1143 activates HIV transcription via NF-kB signaling by degrading the ubiquitin ligase baculoviral IAP repeat-containing 2 (BIRC2), a repressor of the non-canonical NF-kB pathway. Debio 1143-induced BIRC2 degradation results in the accumulation of NF-κB-inducing kinase (NIK) and proteolytic cleavage of p100 into p52, leading to nuclear translocation of p52 and RELB. Debio 1143 greatly enhances the binding of RELB to the HIV-1 LTR. These data indicate that Debio 1143 activates the non-canonical NF-kB signaling pathway by promoting the binding of RELB:p52 complexes to the HIV-1 LTR, resulting in the activation of the LTR-dependent HIV-1 transcription. Importantly, Debio 1143 reverses viral latency in HIV-1 latent T cell lines. Using knockdown (siRNA BIRC2), knockout (CRIPSR NIK) and proteasome machinery neutralization (MG132) approaches, we found that Debio 1143-mediated HIV latency reversal is BIRC2 degradation- and NIK stabilization-dependent. Debio 1143 also reverses HIV-1 latency in resting CD4+ T cells derived from ART-treated patients or HIV-1-infected humanized mice under ART. Interestingly, daily oral administration of Debio 1143 in cancer patients at well-tolerated doses elicited BIRC2 target engagement in PBMCs and induced a moderate increase in cytokines and chemokines mechanistically related to NF-kB signaling. In conclusion, we provide strong evidences that the IAPa Debio 1143, by initially activating the non-canonical NF-kB signaling and subsequently reactivating HIV-1 transcription, represents a new attractive viral latency reversal agent (LRA).},
language = {eng},
number = {2},
journal = {PloS One},
author = {Bobardt, Michael and Kuo, Joseph and Chatterji, Udayan and Chanda, Sumit and Little, Susan J. and Wiedemann, Norbert and Vuagniaux, Gregoire and Gallay, Philippe A.},
year = {2019},
pmid = {30716099},
pmcid = {PMC6361451},
pages = {e0211746},
}
Downloads: 0
{"_id":"AG8cixYNbzoE8t9qv","bibbaseid":"bobardt-kuo-chatterji-chanda-little-wiedemann-vuagniaux-gallay-theinhibitorapoptosisproteinantagonistdebio1143isanattractivehiv1latencyreversalcandidate-2019","author_short":["Bobardt, M.","Kuo, J.","Chatterji, U.","Chanda, S.","Little, S. J.","Wiedemann, N.","Vuagniaux, G.","Gallay, P. A."],"bibdata":{"bibtype":"article","type":"article","title":"The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate","volume":"14","issn":"1932-6203","doi":"10.1371/journal.pone.0211746","abstract":"Antiretroviral therapy (ART) suppresses HIV replication, but does not cure the infection because replication-competent virus persists within latently infected CD4+ T cells throughout years of therapy. These reservoirs contain integrated HIV-1 genomes and can resupply active virus. Thus, the development of strategies to eliminate the reservoir of latently infected cells is a research priority of global significance. In this study, we tested efficacy of a new inhibitor of apoptosis protein antagonist (IAPa) called Debio 1143 at reversing HIV latency and investigated its mechanisms of action. Debio 1143 activates HIV transcription via NF-kB signaling by degrading the ubiquitin ligase baculoviral IAP repeat-containing 2 (BIRC2), a repressor of the non-canonical NF-kB pathway. Debio 1143-induced BIRC2 degradation results in the accumulation of NF-κB-inducing kinase (NIK) and proteolytic cleavage of p100 into p52, leading to nuclear translocation of p52 and RELB. Debio 1143 greatly enhances the binding of RELB to the HIV-1 LTR. These data indicate that Debio 1143 activates the non-canonical NF-kB signaling pathway by promoting the binding of RELB:p52 complexes to the HIV-1 LTR, resulting in the activation of the LTR-dependent HIV-1 transcription. Importantly, Debio 1143 reverses viral latency in HIV-1 latent T cell lines. Using knockdown (siRNA BIRC2), knockout (CRIPSR NIK) and proteasome machinery neutralization (MG132) approaches, we found that Debio 1143-mediated HIV latency reversal is BIRC2 degradation- and NIK stabilization-dependent. Debio 1143 also reverses HIV-1 latency in resting CD4+ T cells derived from ART-treated patients or HIV-1-infected humanized mice under ART. Interestingly, daily oral administration of Debio 1143 in cancer patients at well-tolerated doses elicited BIRC2 target engagement in PBMCs and induced a moderate increase in cytokines and chemokines mechanistically related to NF-kB signaling. In conclusion, we provide strong evidences that the IAPa Debio 1143, by initially activating the non-canonical NF-kB signaling and subsequently reactivating HIV-1 transcription, represents a new attractive viral latency reversal agent (LRA).","language":"eng","number":"2","journal":"PloS One","author":[{"propositions":[],"lastnames":["Bobardt"],"firstnames":["Michael"],"suffixes":[]},{"propositions":[],"lastnames":["Kuo"],"firstnames":["Joseph"],"suffixes":[]},{"propositions":[],"lastnames":["Chatterji"],"firstnames":["Udayan"],"suffixes":[]},{"propositions":[],"lastnames":["Chanda"],"firstnames":["Sumit"],"suffixes":[]},{"propositions":[],"lastnames":["Little"],"firstnames":["Susan","J."],"suffixes":[]},{"propositions":[],"lastnames":["Wiedemann"],"firstnames":["Norbert"],"suffixes":[]},{"propositions":[],"lastnames":["Vuagniaux"],"firstnames":["Gregoire"],"suffixes":[]},{"propositions":[],"lastnames":["Gallay"],"firstnames":["Philippe","A."],"suffixes":[]}],"year":"2019","pmid":"30716099","pmcid":"PMC6361451","pages":"e0211746","bibtex":"@article{bobardt_inhibitor_2019,\n\ttitle = {The inhibitor apoptosis protein antagonist {Debio} 1143 {Is} an attractive {HIV}-1 latency reversal candidate},\n\tvolume = {14},\n\tissn = {1932-6203},\n\tdoi = {10.1371/journal.pone.0211746},\n\tabstract = {Antiretroviral therapy (ART) suppresses HIV replication, but does not cure the infection because replication-competent virus persists within latently infected CD4+ T cells throughout years of therapy. These reservoirs contain integrated HIV-1 genomes and can resupply active virus. Thus, the development of strategies to eliminate the reservoir of latently infected cells is a research priority of global significance. In this study, we tested efficacy of a new inhibitor of apoptosis protein antagonist (IAPa) called Debio 1143 at reversing HIV latency and investigated its mechanisms of action. Debio 1143 activates HIV transcription via NF-kB signaling by degrading the ubiquitin ligase baculoviral IAP repeat-containing 2 (BIRC2), a repressor of the non-canonical NF-kB pathway. Debio 1143-induced BIRC2 degradation results in the accumulation of NF-κB-inducing kinase (NIK) and proteolytic cleavage of p100 into p52, leading to nuclear translocation of p52 and RELB. Debio 1143 greatly enhances the binding of RELB to the HIV-1 LTR. These data indicate that Debio 1143 activates the non-canonical NF-kB signaling pathway by promoting the binding of RELB:p52 complexes to the HIV-1 LTR, resulting in the activation of the LTR-dependent HIV-1 transcription. Importantly, Debio 1143 reverses viral latency in HIV-1 latent T cell lines. Using knockdown (siRNA BIRC2), knockout (CRIPSR NIK) and proteasome machinery neutralization (MG132) approaches, we found that Debio 1143-mediated HIV latency reversal is BIRC2 degradation- and NIK stabilization-dependent. Debio 1143 also reverses HIV-1 latency in resting CD4+ T cells derived from ART-treated patients or HIV-1-infected humanized mice under ART. Interestingly, daily oral administration of Debio 1143 in cancer patients at well-tolerated doses elicited BIRC2 target engagement in PBMCs and induced a moderate increase in cytokines and chemokines mechanistically related to NF-kB signaling. In conclusion, we provide strong evidences that the IAPa Debio 1143, by initially activating the non-canonical NF-kB signaling and subsequently reactivating HIV-1 transcription, represents a new attractive viral latency reversal agent (LRA).},\n\tlanguage = {eng},\n\tnumber = {2},\n\tjournal = {PloS One},\n\tauthor = {Bobardt, Michael and Kuo, Joseph and Chatterji, Udayan and Chanda, Sumit and Little, Susan J. and Wiedemann, Norbert and Vuagniaux, Gregoire and Gallay, Philippe A.},\n\tyear = {2019},\n\tpmid = {30716099},\n\tpmcid = {PMC6361451},\n\tpages = {e0211746},\n}\n\n\n\n","author_short":["Bobardt, M.","Kuo, J.","Chatterji, U.","Chanda, S.","Little, S. J.","Wiedemann, N.","Vuagniaux, G.","Gallay, P. A."],"key":"bobardt_inhibitor_2019","id":"bobardt_inhibitor_2019","bibbaseid":"bobardt-kuo-chatterji-chanda-little-wiedemann-vuagniaux-gallay-theinhibitorapoptosisproteinantagonistdebio1143isanattractivehiv1latencyreversalcandidate-2019","role":"author","urls":{},"metadata":{"authorlinks":{}},"downloads":0,"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/ucsdpirc","dataSources":["q7QJpHKwWD5taSmia"],"keywords":[],"search_terms":["inhibitor","apoptosis","protein","antagonist","debio","1143","attractive","hiv","latency","reversal","candidate","bobardt","kuo","chatterji","chanda","little","wiedemann","vuagniaux","gallay"],"title":"The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate","year":2019}